Thursday, 30 May 2013

Two new GlaxoSmithKline (GSK) drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved for the treatment of patients with advanced melanoma by the U.S. Food and Drug Administration (FDA). Melanoma is the most dangerous form of skin cancer and the number one cause of death from skin disease. According to the National Cancer Institute, about 76,690 people will be diagnosed with melanoma in the U.S. in 2013, and about 9,480 will die from the disease...


Post a Comment


Powered by Blogger.

ads 3

Popular Posts

ads 4

ads 5